Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sweeping FDA Changes Could Have “Disastrous Consequences” For Biotech Investment

Executive Summary

Lowering the bar on drug approval standards would create a challenging environment for biotech investors, warned Jonathan Leff, a partner at the health care investment firm Deerfield, during the BIO CEO & Investor Conference.


Related Content

US FDA Commissioner Search: Pharma’s Preferred Candidate Is Gottlieb
Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan
CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does


Related Companies